


COST ANALYSIS OF REMDESIVIR AND NIRMATRELVIR/RITONAVIR FOR THE EARLY TREATMENT OF COVID19 VULNERABLE PATIENTS

Berti G1, Mengato D2, Mazzitelli M3, Cattelan AM3, Venturini F2, Baldi I1

1. Unit of Biostatistics, Epidemiology, and Public Health, Department of Cardiac, Thoracic, and Vascular Sciences, University of Padua
2. Hospital Pharmacy Unit, Azienda Ospedale-University of Padua
3. Infectious and Tropical Diseases Unit, Azienda Ospedale-University of Padua

Why are we still talking about COVID-19?

Despite the end of the global health emergency, there is a vulnerable segment of the population that is at increased risk of developing the severe form of COVID-19. To avoid this, two antiviral drugs can be used for the early treatment of the disease.



REMDESIVIR
• Intravenous administration
• 3-days therapy
• Patients with CKD

NIRMATRELVIR/RITONAVIR
• Oral administration
• 5 days therapy
• Many drug interactions

Objective

The objective of this study is to carry out a cost analysis between the two therapies used in the early treatment of severe COVID-19, considering their efficacy in preventing hospitalisation and serious adverse events, their ex-factory price and the costs necessary for administration. Finally, a Budget Impact Analysis was performed on the reality of the University Hospital of Padua.


Methods




Main results

NETWORK META-ANALYSIS


Risk Relative for Hospitalization



Risk Relative for Adverse events



TIME-FLOW FOR REMDESIVIR ADMINISTRATION



COST ANALYSIS

COST	SCENARIO A (Remdesivir)	SCENARIO B (Nirmatrelvir-Ritonavir)	DIFFERENCE
EX-FACTORY PRICE	1.840.000,00 €	1.336.290,00 €	503.710,00 €
ADMINISTRATION	76.140,00 €	-	76.140,00 €
HOSPITALIZATION	58.186,01 €	92.515,75 €	- 34.329,74 €
SERIOUS ADVERSE EVENTS	66.677,50 €	61.343,30 €	5.334,20 €
TOTAL	2.041.003,51 €	1.490.149,05 €	550.854,46 €

BUDGET IMPACT ANALYSIS

Patients in early treatment for COVID-19 from october 2023 to september 2024 in University Hospital of Padua




383 Remdesivir + 493 Nirmatrelvir/Ritonavir
Total = 876 patients



Saving estimated for one year of only Nirmatrelvir/Ritonavir treatment
Saving: € 210.977,25

Conclusioni



Bibliografia

1. Zur M, Peselov T, Yanko S, Rotshild V, Matok I. Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: Systematic review and network meta-analysis. Antiviral Res. 1 gennaio 2024;221:105768.
2. Gottlieb 2022. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients | New England Journal of Medicine [Internet]. [citato 12 maggio 2024]. Disponibile su: <https://www.nejm.org/doi/full/10.1056/NEJMoa2116846>
3. Ferrante P. The First Two Years of COVID-19 Hospitalization Characteristics and Costs: Results from the National Discharge Registry. Healthcare. gennaio 2024;12(10):958.
4. Tissot M, Valnet-Rabier MB, Stalder T, Limat S, Davani S, Nerich V. Epidemiology and economic burden of "serious" adverse drug reactions: Real-world evidence research based on pharmacovigilance data. Therapies. 1 maggio 2022;77(3):291–300.